{"entity":{"id":"allogeneic-cell-banking","kind":"technology","name":"Allogeneic donor and iPSC master cell banks","aka":[],"tldr":"Making cell therapies from a healthy donor or stem-cell line in advance, so patients get an off-the-shelf product instead of waiting weeks.","summary":"Off-the-shelf products use healthy-donor T or NK cells (Allogene, Caribou, Cellectis, Takeda/MD Anderson cord-blood NK) or induced pluripotent stem cell master banks (Fate Therapeutics, Century, Shoreline, Cellular Biomedicine) edited to avoid graft-versus-host disease and host rejection. Banking, donor eligibility, and comparability across thousands of doses from one bank are the manufacturing questions; durability of response is the clinical one.","status":"emerging","asOf":"2026-09-08","links":[{"label":"21 CFR Part 1271: human cells, tissues, and cellular and tissue-based products","url":"https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["car-t","car-nk-macrophage","cell-therapy-cold-chain"],"targets":[],"drugs":[],"companies":["caribou"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"A characterised master cell bank (donor or iPSC) is expanded, gene-edited to remove TCR and HLA class I, differentiated if needed, and cryopreserved in hundreds of doses per batch.","strengths":["Immediate availability","Lower cost per dose at scale","Consistent product"],"limitations":["Rejection limits persistence","Editing complexity","Donor-to-donor variability for primary-cell products"]},"route":"/technologies/allogeneic-cell-banking/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"},{"id":"car-nk-macrophage","kind":"technology","name":"CAR-NK & CAR-macrophage","route":"/technologies/car-nk-macrophage/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"cell-therapy-cold-chain","kind":"technology","name":"Cryopreservation and cell-therapy cold chain","route":"/technologies/cell-therapy-cold-chain/"}],"company":[{"id":"caribou","kind":"company","name":"Caribou Biosciences","route":"/companies/caribou/"}],"paper":[{"id":"paper-ucart19-allogeneic-car-t-lancet-2020","kind":"paper","name":"UCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL","route":"/key-papers/paper-ucart19-allogeneic-car-t-lancet-2020/"}]}}